1-methyl-1-(4-methyl-1-naphthyl)ethyl hydroperoxide under gas chromatography-mass spectroscopy (GC–MS) conditions gives 2-((4-methyl-1-naphthyl)oxy)propene as the main product (50.5%), without any detectable traces of the isomeric 2-((5-methyl-1-naphthyl)oxy)propene. This finding excludes the rearrangement pathway of 1-methyl-1-(1-naphthyl)ethyl hydroperoxides to the corresponding 2-(1-naphthyloxy)propenes
CARBOXAMIDE OR SULFONAMIDE SUBSTITUTED THIAZOLES AND RELATED DERIVATIVES AS MODULATORS FOR THE ORPHAN NUCLEAR RECEPTOR ROR[GAMMA]
申请人:Phenex Pharmaceuticals AG
公开号:US20150175562A1
公开(公告)日:2015-06-25
The invention provides modulators for the orphan nuclear receptor RORy and methods for treating RORy mediated diseases by administering these novel RORy modulators to a human or a mammal in need thereof. Specifically, the present invention provides carboxamide or sulfonamide containing cyclic compounds of Formula (1), (1′), (100), (100′), (200) and (200′) and the enantiomers, diastereomers, tautomers, /V-oxides, solvates and pharmaceutically acceptable salts thereof.
CARBOXAMIDE OR SULFONAMIDE SUBSTITUTED NITROGEN-CONTAINING 5-MEMBERED HETEROCYCLES AS MODULATORS FOR THE ORPHAN NUCLEAR RECEPTOR ROR GAMMA
申请人:PHENEX PHARMACEUTICALS AG
公开号:US20150344423A1
公开(公告)日:2015-12-03
The invention provides modulators for the orphan nuclear receptor RORy and methods for treating RORy mediated diseases by administering these novel RORy modulators to a human or a mammal in need thereof. Specifically, the present invention provides carboxamide containing cyclic compounds of Formula (1) to Formula (5) and the enantiomers, diastereomers, tautomers, /V-oxides, solvates and pharmaceutically acceptable salts thereof.